Tafasitamab
- Generic Name
- Tafasitamab
- Brand Names
- Monjuvi, Minjuvi
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1422527-84-1
- Unique Ingredient Identifier
- QQA9MLH692
- Background
Tafasitamab is a humanized, CD19-directed cytolytic monoclonal antibody intended for the treatment of B-cell malignancies. It is produced using recombinant DNA technology in Chinese hamster ovary cells, and contains an IgG1/2 hybrid Fc-domain which has been modified with 2 amino acid substitutions to enhance its cytotoxicity relative to non-engineered anti-C...
- Indication
Tafasitamab is indicated, in combination with lenalidomide, for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) not otherwise specified whom are ineligible for autologous stem cell transplant (ASCT).
- Associated Conditions
- Refractory Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Relapsed Diffuse large B-cell lymphoma NOS
- Associated Therapies
- -
Rituximab, Lenalidomide, Acalabrutinib, Tafasitamab Alone and With Combination Chemotherapy for the Treatment of Newly Diagnosed Non-germinal Center Diffuse Large B-Cell Lymphoma, Smart Stop Study
- First Posted Date
- 2021-07-27
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 60
- Registration Number
- NCT04978584
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Study of Tafasitamab and Lenalinomide Associated to Rituximab in Frontline Diffuse Large B-Cell Lymphoma Patients of 80 y/o or Older
- Conditions
- Interventions
- First Posted Date
- 2021-07-23
- Last Posted Date
- 2024-10-09
- Lead Sponsor
- The Lymphoma Academic Research Organisation
- Target Recruit Count
- 71
- Registration Number
- NCT04974216
- Locations
- 🇧🇪
Clinique Universitaire Saint LUC, Brussels, Belgium
🇧🇪CHU de Liège, Liège, Belgium
🇧🇪CHRU Mont Godinne, Yvoir, Belgium
Study to Evaluate Tolerability of Iberdomide (CC-220) in Combination With Polatuzumab Vedotin Plus Rituximab or Tafasitamab or Rituximab Plus Chemotherapy in B-cell Lymphoma
- First Posted Date
- 2021-05-11
- Last Posted Date
- 2021-10-05
- Lead Sponsor
- Celgene
- Registration Number
- NCT04882163
- Locations
- 🇬🇧
Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom
🇺🇸Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸Avera Cancer Institute, Sioux Falls, South Dakota, United States
Tafasitamab + Lenalidomide + R-CHOP Versus R-CHOP in Newly Diagnosed High-intermediate and High Risk DLBCL Patients
- Conditions
- Interventions
- First Posted Date
- 2021-04-01
- Last Posted Date
- 2024-08-09
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 899
- Registration Number
- NCT04824092
- Locations
- 🇨🇳
Morphsys Research Site, Taoyuan, Taiwan
🇬🇧MorphoSys Research Site, Wolverhampton, United Kingdom
🇷🇺Morphosys research site, UFA, Russian Federation
A Study Evaluating Safety, PK, and Efficacy of Tafasitamab and Parsaclisib in Participants With Relapsed/Refractory Non Hodgkin Lymphoma (R/R NHL) or Chronic Lymphocytic Leukemia (CLL)
- Conditions
- Interventions
- First Posted Date
- 2021-03-22
- Last Posted Date
- 2024-11-18
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 54
- Registration Number
- NCT04809467
- Locations
- 🇺🇸
University of Southern California, Los Angeles, California, United States
🇺🇸Indiana Blood and Marrow Transplantation, Indianapolis, Indiana, United States
🇺🇸Ohio State University, Columbus, Ohio, United States
A Phase 3 Study to Assess Efficacy and Safety of Tafasitamab Plus Lenalidomide and Rituximab Compared to Placebo Plus Lenalidomide and Rituximab in Patients With Relapsed/Refractory (R/R) Follicular Lymphoma or Marginal Zone Lymphoma.
- Conditions
- Interventions
- First Posted Date
- 2020-12-22
- Last Posted Date
- 2024-08-15
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 654
- Registration Number
- NCT04680052
- Locations
- 🇺🇸
John Muir Health Clinical Research Center, Concord, California, United States
🇺🇸Metro-Minnesota Community Oncology Reserch Consortium (Mmcorc), Saint Louis Park, Minnesota, United States
🇺🇸Hattiesburg Clinic Hematology, Hattiesburg, Mississippi, United States
To Assess the Safety and Tolerability of Tafasitamab Alone or in Combination With Other Drugs in Japanese Participants With Non-Hodgkins Lymphoma (NHL)
- Conditions
- Interventions
- First Posted Date
- 2020-12-09
- Last Posted Date
- 2024-12-10
- Lead Sponsor
- Incyte Biosciences Japan GK
- Target Recruit Count
- 65
- Registration Number
- NCT04661007
- Locations
- 🇯🇵
Aichi Cancer Center Hospital, Aichi, Japan
🇯🇵Chiba Cancer Center, Chiba, Japan
🇯🇵National Cancer Center Hospital East, Chiba, Japan
Study of Acalabrutinib and Tafasitamab in MZL Patients
- Conditions
- Interventions
- First Posted Date
- 2020-11-30
- Last Posted Date
- 2024-10-24
- Target Recruit Count
- 26
- Registration Number
- NCT04646395
- Locations
- 🇦🇹
University of Wien, Wien, Austria
🇮🇹ASST Spedali Civili di Brescia, Brescia, Italy
🇮🇹Fondazione IRCCS - Istituto Nazionale dei Tumori, Milano, Italy
Study of Selinexor in Combination With Backbone Treatments or Novel Therapies In Participants With Relapsed or Refractory (RR) Diffuse Large B-Cell Lymphoma (DLBCL)
- First Posted Date
- 2020-10-29
- Last Posted Date
- 2023-01-25
- Lead Sponsor
- Karyopharm Therapeutics Inc
- Target Recruit Count
- 350
- Registration Number
- NCT04607772
- Locations
- 🇺🇸
UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, United States
🇺🇸US Oncology - Oncology Associates of Oregon, Eugene, Oregon, United States
🇺🇸University of Texas Southwestern, Dallas, Texas, United States
Phase I Master Protocol of Novel Combination Therapy for Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2019-11-13
- Last Posted Date
- 2024-06-12
- Lead Sponsor
- Canadian Cancer Trials Group
- Target Recruit Count
- 18
- Registration Number
- NCT04161248
- Locations
- 🇨🇦
Kingston Health Sciences Centre, Kingston, Ontario, Canada
🇨🇦University Health Network, Toronto, Ontario, Canada
🇨🇦The Jewish General Hospital, Montreal, Quebec, Canada
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.